{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Symptomatic+Respiratory+Disease&page=3", "query": { "condition": "Symptomatic Respiratory Disease", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 123, "total_pages": 13, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Symptomatic+Respiratory+Disease&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Symptomatic+Respiratory+Disease&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-12T02:42:34.276Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05897541", "title": "Phase 3 Study of S-217622 in Prevention of Symptomatic SARS-CoV-2 Infection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "SARS-CoV-2 Infection" ], "interventions": [ { "name": "S-217622", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Shionogi", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 3701, "start_date": "2023-06-09", "completion_date": "2024-09-18", "has_results": true, "last_update_posted_date": "2026-10-07", "last_synced_at": "2026-10-12T02:42:34.276Z", "location_count": 95, "location_summary": "Birmingham, Alabama • Cullman, Alabama • Phoenix, Arizona + 60 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Cullman", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT05897541" }, { "nct_id": "NCT00920959", "title": "Advair Pediatric Once-Daily", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Asthma" ], "interventions": [ { "name": "FP 100mcg", "type": "DRUG" }, { "name": "FSC 100/50mcg", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "4 Years", "maximum_age": "11 Years", "sex": "ALL", "summary": "4 Years to 11 Years" }, "enrollment_count": 908, "start_date": "2001-11", "completion_date": "2004-01", "has_results": false, "last_update_posted_date": "2016-09-15", "last_synced_at": "2026-10-12T02:42:34.276Z", "location_count": 141, "location_summary": "Ozark, Alabama • Tucson, Arizona • Little Rock, Arkansas + 118 more", "locations": [ { "city": "Ozark", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Beverly Hills", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00920959" }, { "nct_id": "NCT02141854", "title": "Efficacy and Safety Study of FP MDPI Compared With FS MDPI in Adolescent and Adult Patients With Persistent Asthma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Asthma" ], "interventions": [ { "name": "FS MDPI", "type": "DRUG" }, { "name": "Fp MDPI", "type": "DRUG" }, { "name": "Placebo MDPI", "type": "DRUG" }, { "name": "Albuterol/salmeterol HFA MDI", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Teva Branded Pharmaceutical Products R&D, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 882, "start_date": "2014-06", "completion_date": "2015-09", "has_results": true, "last_update_posted_date": "2021-11-09", "last_synced_at": "2026-10-12T02:42:34.276Z", "location_count": 85, "location_summary": "Birmingham, Alabama • Little Rock, Alaska • Phoenix, Arizona + 74 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Little Rock", "state": "Alaska" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Costa Mesa", "state": "California" }, { "city": "Encinitas", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02141854" }, { "nct_id": "NCT02139644", "title": "Study of Fluticasone Propionate MDPI Compared With Fluticasone/Salmeterol MDPI in Adolescent and Adult Patients With Persistent Asthma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Asthma" ], "interventions": [ { "name": "FS MDPI", "type": "DRUG" }, { "name": "Fp MDPI", "type": "DRUG" }, { "name": "Placebo MDPI", "type": "DRUG" }, { "name": "albuterol/salbutamol", "type": "DRUG" }, { "name": "Beclomethasone dipropionate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Teva Branded Pharmaceutical Products R&D, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 787, "start_date": "2014-06", "completion_date": "2015-09", "has_results": true, "last_update_posted_date": "2021-11-12", "last_synced_at": "2026-10-12T02:42:34.276Z", "location_count": 76, "location_summary": "Birmingham, Alabama • Glendale, Arizona • Cypress, California + 64 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Cypress", "state": "California" }, { "city": "Encinitas", "state": "California" }, { "city": "Fountain Valley", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02139644" }, { "nct_id": "NCT04822701", "title": "A Study to Test BI 767551 in People With Mild to Moderate Symptoms of COVID-19", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "COVID-19" ], "interventions": [ { "name": "BI 767551 intravenous", "type": "DRUG" }, { "name": "BI 767551 inhaled", "type": "DRUG" }, { "name": "Placebo intravenous", "type": "DRUG" }, { "name": "Placebo inhaled", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5, "start_date": "2021-04-21", "completion_date": "2021-10-04", "has_results": true, "last_update_posted_date": "2022-07-28", "last_synced_at": "2026-10-12T02:42:34.276Z", "location_count": 4, "location_summary": "Miami Springs, Florida • Amarillo, Texas • Houston, Texas + 1 more", "locations": [ { "city": "Miami Springs", "state": "Florida" }, { "city": "Amarillo", "state": "Texas" }, { "city": "Houston", "state": "Texas" }, { "city": "Victoria", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04822701" }, { "nct_id": "NCT00452699", "title": "A 12-Month Study Comparing Fluticasone Propionate/Salmeterol (ADVAIR) DISKUS Combination Product 250/50mcg BID To Fluticasone Propionate (FLOVENT) DISKUS 250 mcg BID In Symptomatic Subjects With Asthma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Asthma" ], "interventions": [ { "name": "Fluticasone Propionate/salmeterol xinofoate 250/50 mcg BID", "type": "DRUG" }, { "name": "Fluticasone propionate 250 mcg BID", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 621, "start_date": "2007-05", "completion_date": "2009-05", "has_results": true, "last_update_posted_date": "2016-12-08", "last_synced_at": "2026-10-12T02:42:34.276Z", "location_count": 58, "location_summary": "Scottsdale, Arizona • Little Rock, Arkansas • Fountain Valley, California + 48 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Rancho Mirage", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00452699" }, { "nct_id": "NCT00917111", "title": "The Effect of Nasal Carbon Dioxide (CO2) in the Symptomatic Treatment of Seasonal Allergic Rhinitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Seasonal Allergic Rhinitis" ], "interventions": [ { "name": "Nasal CO2", "type": "DRUG" }, { "name": "Inactive Placebo Gas", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Capnia, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 33, "start_date": "2009-07", "completion_date": "2009-11", "has_results": false, "last_update_posted_date": "2012-08-15", "last_synced_at": "2026-10-12T02:42:34.276Z", "location_count": 1, "location_summary": "Omaha, Nebraska", "locations": [ { "city": "Omaha", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT00917111" }, { "nct_id": "NCT04565665", "title": "Study of Cord Blood Derived Mesenchymal Stem Cells for Treatment of Moderate, Severe or Critical Pneumonia", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "COVID-19 Infection", "COVID-19-Associated Acute Respiratory Distress Syndrome", "Hematopoietic and Lymphoid Cell Neoplasm", "Malignant Solid Neoplasm", "Symptomatic COVID-19 Infection Laboratory-Confirmed" ], "interventions": [ { "name": "Best Practice", "type": "OTHER" }, { "name": "Mesenchymal Stem Cell", "type": "BIOLOGICAL" } ], "intervention_types": [ "OTHER", "BIOLOGICAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 65, "start_date": "2020-07-29", "completion_date": "2027-10-30", "has_results": false, "last_update_posted_date": "2026-10-05", "last_synced_at": "2026-10-12T02:42:34.276Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04565665" }, { "nct_id": "NCT04508023", "title": "A Study of Rivaroxaban to Reduce the Risk of Major Venous and Arterial Thrombotic Events, Hospitalization and Death in Medically Ill Outpatients With Acute, Symptomatic Coronavirus Disease 2019 (COVID-19) Infection", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Coronavirus Disease 2019 (COVID-19)" ], "interventions": [ { "name": "Rivaroxaban", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" }, { "name": "Standard of Care (SOC)", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1284, "start_date": "2020-08-13", "completion_date": "2022-06-01", "has_results": true, "last_update_posted_date": "2023-07-18", "last_synced_at": "2026-10-12T02:42:34.276Z", "location_count": 17, "location_summary": "Tucson, Arizona • Los Angeles, California • Oakland, California + 13 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Oakland", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04508023" }, { "nct_id": "NCT02649894", "title": "Safety and Effectiveness of a New Pleural Catheter for Symptomatic, Recurrent, MPEs Versus Approved Pleural Catheter", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Malignant Pleural Effusion" ], "interventions": [ { "name": "Active Comparator: Approved Uncoated PleurX Indwelling Pleural Catheter", "type": "DEVICE" }, { "name": "Experimental: Silver Nitrate Coated Indwelling Pleural Catheter (SNCIPC)", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "C. R. Bard", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 119, "start_date": "2016-05", "completion_date": "2018-04-18", "has_results": true, "last_update_posted_date": "2025-12-11", "last_synced_at": "2026-10-12T02:42:34.276Z", "location_count": 16, "location_summary": "Huntsville, Alabama • Stanford, California • Tampa, Florida + 12 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Stanford", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT02649894" } ] }